Form 4: ACHIEVE CFO Mark Oki Granted 180,000 Stock Options

ACHIEVE LIFE SCIENCES, INC. Chief Financial Officer Mark K. Oki was granted 180,000 stock options with an exercise price of $4.36, vesting over four years.

Summary

• Mark K. Oki, Chief Financial Officer of ACHIEVE LIFE SCIENCES, INC. (ACHV), acquired 180,000 derivative securities in the form of stock options.
• The transaction date for this grant was January 28, 2025.
• Each stock option has an exercise price of $4.36.
• The options will begin to vest as to 1/4 of the total award on January 28, 2026, and thereafter in substantially equal monthly installments over 36 months.
• Vesting is contingent upon Mr. Oki's continued provision of service to the Issuer on each vesting date.
• The expiration date for these stock options is January 28, 2036.
• Following this transaction, Mr. Oki beneficially owns 180,000 derivative securities directly.

Sentiment

Score: 6

Explanation: StockSavvy.ai views this as a neutral to slightly positive event, as it represents a routine compensation action that aligns management incentives with shareholder interests without indicating any immediate operational or financial changes.

Positives

• The grant of stock options aligns the Chief Financial Officer's financial interests with those of shareholders, incentivizing long-term company performance.
• Equity compensation is a standard practice for retaining and motivating key executives.

Future Outlook

The stock options are subject to a vesting schedule, with the first portion vesting on January 28, 2026, and the remainder vesting monthly over the subsequent 36 months, contingent on the CFO's continued service.

Industry Context

StockSavvy.ai notes that the grant of stock options to a Chief Financial Officer is a common form of executive compensation across the biotechnology and pharmaceutical industries. This practice aims to align management's long-term incentives with shareholder value creation, particularly in companies like ACHIEVE LIFE SCIENCES, INC. which are often focused on long-term drug development and commercialization milestones.

Comparison to Industry Standards

• Equity grants, such as stock options, are a standard component of executive compensation packages in the biotechnology sector, comparable to practices at companies like Biogen Inc. or Gilead Sciences, Inc. for their senior leadership.
• The vesting schedule, typically over three to four years, is also consistent with industry norms designed to encourage executive retention and sustained performance.

Stakeholder Impact

• Shareholders: The grant of options to the CFO can be seen as a positive for shareholders, as it ties executive compensation to the company's stock performance, potentially motivating the CFO to enhance shareholder value.
• Employees: This filing specifically relates to executive compensation and does not directly impact the broader employee base, though it reflects standard compensation practices at the executive level.

Next Steps

• The stock options will begin to vest on January 28, 2026, with subsequent monthly vesting installments over 36 months.
• The Chief Financial Officer will need to continue providing service to the Issuer to meet the vesting conditions.

Key Dates

Keywords

ACHV, stock options, insider transaction, equity compensation, CFO, Form 4, Achieve Life Sciences